Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

EarlySense Patient Monitoring System Saw 40 Percent Increase in Adoption in 2016

XTALKS VITALS NEWS

Patient

The contact-free system was used to monitor the vital signs of over 115,000 patients in hospital facilities and home environments last year.

Share this!

January 25, 2017 | by Sarah Hand, M.Sc.

In 2016, adoption of the EarlySense continuous medical monitoring system increased by almost 40 percent, to include over 105 clinical care areas around the world. The contact-free system was used to monitor the vital signs of over 115,000 patients in hospital facilities and home environments last year.

According to statistically analysis conducted by EarlySense, the company estimates that their monitoring system may have helped save more than 550 lives, and prevent 800 falls and over 45,000 hospitalization days. In the absence of EarlySense monitoring and alerts, these events would cost a combined $30 million.

“In 2016, EarlySense significantly expanded the reach and impact of our hospital-proven technology and we are pleased to achieve these milestones,” said Avner Halperin, Founder and CEO of EarlySense. “Almost daily we hear from medical institutions about how they saved a life or dramatically improved a patient's outcome by leveraging EarlySense – it is extremely rewarding. It is clear that continuous monitoring is poised to become a global standard of care, and we look forward to providing valuable health insight and support to facilities, health teams and patients in 2017 and beyond.”



EarlySense has since made some upgrades to it continuous monitoring medical devices. The company launched InSight, a product aimed at reducing patient falls and hospital admissions in nursing facilities. A new Multi-Parameter Alert was also introduced, which monitors a patient’s heart and breathing rates to help healthcare providers in the early detection of sepsis.

“Non-ICU patients are at risk for a variety of complications during hospitalization and early warning signs are often subtle and not easily detected,” said Halperin. “By providing healthcare professionals with continuous data and timely indication of change through our Multi-Parameter Alert, precious time can be saved enabling early detection and treatment of sepsis as well as other potential adverse events.”

EarlySense is also breaking into the consumer health space by introducing its LIVE health monitoring solution. LIVE is primarily a sleep monitor, which EarlySense claims is the first consumer health monitoring product to be based on medically-proven technology.


Keywords: Patient Monitoring, Medical Device, Healthcare


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
Lavazza Acquires Controlling Stake in Canada’s Kicking Horse Coffee

May 26, 2017 - Italian coffee company Lavazza, has secured an 80 percent equity stake in Canadian organic and fair-trade coffee company Kicking Horse Coffee, in a deal worth CAD$215 million.

Featured In: Food News


FDA First: Keytruda Approved for Cancer Treatment Based on Biomarker Alone

May 25, 2017 - For the first time, the FDA has approved a cancer treatment for solid tumors based on the presence of a biomarker, as opposed to specifying a tissue of origin.

Featured In: Biotech News


One Year of Medically Assisted Dying in Canada

May 25, 2017 - In June of 2016, the federal government of Canada passed legislation to legalize medically assisted dying.

Featured In: Life Science News


LEAVE A COMMENT
 
  
THE XTALKS VITALS INDUSTRY BLOG

Top 5 Most Impactful Tweets in Life Sciences During the Last Week

REGISTER FOR THESE WEBINARS

EU IVD Regulation: Top Five Changes for Medical Device Manufacturers to Consider


Thermal Processing Systems for the Food Industry: A Guide to Selecting Thermal Equipment and Technology


Rare Disease & Orphan Drug Development: Cost-Efficient Trial Design to Minimize Cash Burn


eTMF Workflows: Active eTMF to Improve the Quality of Clinical Trials


Copyright © 2016-2017 Honeycomb Worldwide Inc.